Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

HEPATITIS-B VIRAL MARKERS IN SEVERE VIRAL-HEPATITIS - INFLUENCE OF STEROID-THERAPY HEPATOLOGY Greenberg, H. B., Robinson, W. S., Knauer, C. M., Gregory, P. B. 1981; 1 (1): 54-57

Abstract

In our double-blind randomized trial of methylprednisolone vs. placebo in severe viral hepatitis, 16 patients with hepatitis B (8 on steroid, 8 on placebo) were followed for at least 4 weeks. Four of the eight patients receiving methylprednisolone eventually died and all patients on placebo survived. Despite marked reduction in serum IgG in steroid-treated patients, the decline in HBsAg titer and disappearance of Dane particle markers was the same in both treatment groups. A nonspecific depression of anti-HBc was noted in patients given steroid. There is no evidence that corticosteroid therapy accelerates viral replication when the acute hepatitis is severe.

View details for Web of Science ID A1981MP47500008

View details for PubMedID 7026400